晚期I型上皮性卵巢癌患者的基因型匹配治疗
研究对55例I型上皮性卵巢癌患者进行前瞻性分子谱检测,35例(64%)发现至少1个体细胞突变,15例入组基因型匹配的I期或II期临床试验,14例KRAS/NRAS突变患者接受MEK抑制剂联合治疗,7例部分缓解,10/10可评估患者出现CA125缓解,结论认为MEK联合治疗在KRAS和/或NRAS突变I型上皮性卵巢癌中是有活性的治疗策略。
要点
- 55例I型上皮性卵巢癌中35例(64%)检出至少1个体细胞突变。
- 15例入组基因型匹配试验,14例KRAS/NRAS突变者接受MEK抑制剂联合治疗。
- 14例可评估者中7例部分缓解、7例疾病稳定、1例疾病进展;10/10可评估者出现CA125缓解。
核心结论
- I型上皮性卵巢癌的基因分型和靶向测序常可识别可靶向的突变。
- KRAS和/或NRAS突变I型上皮性卵巢癌患者接受以MEK为基础的联合匹配治疗是一种有活性的治疗策略。
研究设计与样本
- 前瞻性分子谱检测项目:福尔马林固定石蜡包埋肿瘤组织采用MALDI-ToF质谱平台或Illumina MiSeq TruSeq Amplicon Cancer Panel靶向测序筛查基因组改变。
- 基因型匹配试验的治疗结局采用RECIST 1.1版和妇科癌症工作组CA125相关缓解标准进行回顾性评估。
- 55例I型上皮性卵巢癌患者接受分子谱检测,其中低级别浆液性41例(75%)、透明细胞9例(16%)、黏液性5例(9%)。
主要发现
- 35例(64%)发现至少1个体细胞突变:KRAS 23例、NRAS 6例、PIK3CA 5例、PTEN 2例、BRAF 1例、AKT 1例、TP53 1例、CTNNB1 1例。
- 15例随后入组基因型匹配的I期或II期试验,包括14例KRAS/NRAS突变患者接受MEK抑制剂靶向联合治疗。
- 14例RECIST可评估患者中,部分缓解7例、疾病稳定7例、疾病进展1例。
- 10/10例可评估的KRAS/NRAS突变患者接受MEK抑制剂联合治疗后观察到CA125缓解。
临床怎么用
- 作者认为,对I型上皮性卵巢癌进行基因分型和靶向测序常可识别可靶向的突变。
- 作者认为,KRAS和/或NRAS突变I型上皮性卵巢癌患者接受以MEK为基础的联合匹配治疗是一种有活性的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic alterations that activate the MAPK signaling pathway frequently occur in Type I Epithelial Ovarian Cancers (EOCs). We evaluated therapeutic response outcomes in patients with type I EOC treated with genotype-matched therapy on clinical trials enrolled in a prospective molecular profiling program. MATERIAL AND METHODS: Formalin fixed paraffin embedded tumor tissues were prospectively screened for genomic alterations using MALDI-ToF mass-spectrometry platform or targeted sequencing using the Illumina MiSeq TruSeq Amplicon Cancer Panel. Treatment outcomes on genotype-matched trials were retrospectively reviewed using RECIST version 1.1 and Gynecological Cancer Intergroup CA125 related-response criteria RESULTS: 55 patients with type I EOC underwent molecular profiling, 41 (75%) low grade serous (LGS), 9 (16%) clear cell (CC), and 5 (9%) mucinous (MC) histologies. Thirty-five patients (64%) were found to have ≥1 somatic mutations: 23 KRAS, 6 NRAS, 5 PIK3CA, 2 PTEN, 1 BRAF, 1 AKT, 1 TP53, and 1 CTNNB1. Fifteen patients were subsequently enrolled in genotype-matched phase I or II trials, including 14 patients with KRAS/NRAS mutations treated with MEK inhibitor targeted combinations. Among 14 RECIST evaluable patients, there were 7 partial responses (PR), 7 stable disease (SD) and 1 disease progression (PD). CA125 responses were observed in 10/10 evaluable KRAS/NRAS mutant patients treated with MEK inhibitor combinations CONCLUSIONS: Genotyping and targeted sequencing of Type I EOCs frequently identifies actionable mutations. Matched treatment with MEK-based combination therapy in KRAS and/or NRAS mutant type I EOC patients is an active therapeutic strategy.
引用
- Spreafico A, Oza AM, Clarke BA, et al. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecol Oncol. 2017. PMID: 28062115. doi:10.1016/j.ygyno.2016.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。